Table 4 Univariate and multivariate Cox proportional hazards models for iDFS and OS considering TILs (negative, ≤5%, >5%), tumor size, lymph node metastases, grade, and molecular subtype.
Invasive disease-free survival (iDFS) | Overall survival (OS) | |||||
|---|---|---|---|---|---|---|
HR | CI 95% | p value | HR | CI 95% | p value | |
Univariate COX | ||||||
TILs in tumor | ||||||
Negative | 1 | 0.004 | 1 | <0.001 | ||
≤5% | 1.93 | 1.17–3.23 | 4.12 | 1.91–10.05 | ||
>5% | 2.93 | 1.40–5.74 | 5.31 | 1.79–15.35 | ||
Grade | ||||||
G1 | 1 | 0.09 | 1 | 0.48 | ||
G2 | 2.15 | 0.83–7.85 | 1.04 | 0.37–4.34 | ||
G3 | 3.42 | 1.12–13.58 | 1.85 | 0.49–8.78 | ||
Tumor size | ||||||
pT1 | 1 | 0.38 | 1 | 0.19 | ||
pT2 | 1.41 | 0.84–2.31 | 1.64 | 0.79–3.27 | ||
pT3 | 1.36 | 0.57–2.77 | 2.17 | 0.76–5.2 | ||
Lymph node metastases | ||||||
pN0 | 1 | 0.003 | 1 | <0.001 | ||
pN1 | 1.41 | 0.78–2.42 | 2.41 | 1.11–5.03 | ||
pN2 | 2.98 | 1.33–5.92 | 5.9 | 2.21–13.87 | ||
pN3 | 4.61 | 1.68–10.31 | 6.99 | 1.83–19.77 | ||
Molecular subtype | ||||||
Luminal A | 1 | 0.22 | 1 | 0.005 | ||
Luminal B | 1.51 | 0.95–2.41 | 2.99 | 1.53–6.12 | ||
HER2-positive | 0.52 | 0.06–1.93 | 0.53 | 0.004–4.02 | ||
Triple-negative | 1.27 | 0.26–3.79 | 3.81 | 0.74–12.77 | ||
Prominent nucleoli | ||||||
No | 1 | 0.05 | 1 | 0.049 | ||
Yes | 1.62 | 1–2.59 | 1.95 | 1–3.71 | ||
Multivariate COX | ||||||
TILs in tumor | ||||||
Negative | 1 | 0.001 | 1 | <0.001 | ||
≤5% | 2.03 | 1.23–3.42 | 4.38 | 2.02–10.73 | ||
>5% | 3.47 | 1.61–7.02 | 6.15 | 1.98–18.60 | ||
Lymph node metastases | ||||||
pN0 | 1 | 0.003 | 1 | 0.003 | ||
pN1 | 1.51 | 0.83–2.65 | 2.66 | 1.20–5.75 | ||
pN2 | 3.16 | 1.37–6.41 | 4.91 | 1.82–11.73 | ||
pN3 | 4.33 | 1.55–9.97 | 6.29 | 1.60–18.74 | ||
Molecular subtype | ||||||
Luminal A | 1 | 0.03 | 1 | <0.001 | ||
Luminal B | 1.58 | 0.97–2.55 | 3.06 | 1.54–6.36 | ||
HER2-positive | 0.26 | 0.03–1.02 | 0.24 | 0.002–1.85 | ||
Triple-negative | 1.33 | 0.27–4.05 | 4.60 | 0.87–16.22 | ||
